Eugene Gerner, PhD | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
researchers

Eugene Gerner, PhD

Researcher
Director
Gastrointestinal Cancer Program
Arizona Cancer Center
Places : The University of Arizona Cancer Center

CEO, Cancer Prevention Pharmaceuticals (CPP)

Cancer Prevention Pharmaceuticals (CPP) is a company in the late stages of developing drugs and drug combinations to treat people with risk factors for cancer. Some of these people have genetic risk factors, such as defects in the adenomatous poly posits coli tumor suppressor gene which cause the familial adenomatous polyposis (FAP) syndrome. Others have sporadic risk factors, such as prior colorectal cancer or neuroblastoma with amplified copies of the MYCN oncogene. CPP is also developing companion diagnostics for its drug therapies.

view full profile

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close